Adempas (Riociguat) Patent Expiration, LOE Window & CMS Spending
Adempas (Riociguat) by Bayer: FDA Orange Book core substance LOE 2034-02-18, 1 AB generics, $802.7M 2024 CMS Part D & Medicaid spend, and 20 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Bayer |
| FDA Application & Pathway | N204819 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2034-02-18 |
| Last Listed Patent or Exclusivity Date | 2034-02-18 |
| Orange Book Patents (*PED Extensions) | 4 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $802.7M |
| 2024 Medicare Part D Spend | $694.2M |
| 2024 Medicaid Spend | $108.5M |
| Reported Wholesale Price Change (CA SB 17) | 20 WAC filings (max 19.1% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.
- Predicate Ledger FDA 510(k)Bayer FDA 510(k) & Recall Cohortdevices.meruai.co →
- Protocol Ledger NIH ClinicalTrials.govBayer Clinical Trials & Approvalstrials.meruai.co →
- ERISA Ledger DOL Form 5500Bayer 401(k) & Form 5500 Planerisa.meruai.co →
- Plume Ledger EPA TRI & RCRABayer U.S. TRI & RCRA Facilitieshazmat.meruai.co →